1. 46PPrevalence of homologous recombination deficiency (HRD)-related signatures indicates that a wider range of prostate cancer patients may benefit from PARP-inhibitor therapy. (7th November 2019) Authors: Sztupinszki, Z; Diossy, M; Krzystanek, M; Borcsok, J; Pomerantz, M; Tisza, V; Spisak, S; Rusz, O; Csabai, I; Freedman, M; Szallasi, Z Journal: Annals of oncology Issue: Volume 30(2019)Supplement 7 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Breast cancer brain metastases show increased levels of genomic aberration-based homologous recombination deficiency scores relative to their corresponding primary tumors. (18th June 2018) Authors: Diossy, M; Reiniger, L; Sztupinszki, Z; Krzystanek, M; Timms, K M; Neff, C; Solimeno, C; Pruss, D; Eklund, A C; Tóth, E; Kiss, O; Rusz, O; Cserni, G; Zombori, T; Székely, B; Tímár, J; Csabai, I; Szallasi, Z Journal: Annals of oncology Issue: Volume 29:Number 9(2018) Page Start: 1948 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Corrigendum to: Breast cancer brain metastases show increased levels of genomic aberration-based homologous recombination deficiency scores relative to their corresponding primary tumors. (30th March 2019) Authors: Diossy, M; Reiniger, L; Sztupinszki, Z; Krzystanek, M; Timms, K M; Neff, C; Solimeno, C; Pruss, D; Eklund, A C; Tóth, E; Kiss, O; Rusz, O; Cserni, G; Zombori, T; Székely, B; Kulka, J; Tímár, J; Csabai, I; Szallasi, Z Journal: Annals of oncology Issue: Volume 30:Number 8(2019) Page Start: 1406 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗